Wang 2013.

Methods	Method of randomisation not clear.
Participants	122 breast cancer participants (stage nm; mean age at time of study nm; sex nm) treated with epirubicin (cumulative dose average nm (four cycles of adjuvant chemotherapy); peak dose (i.e. maximal dose received in 1 week) nm; infusion duration nm). Prior anthracycline therapy nm. Prior cardiac radiotherapy nm. Prior cardiac dysfunction: nm.
Interventions	Dexrazoxane (ratio to doxorubicin 10:1; route and timing of dexrazoxane delivery nm) (N = 61) versus no cardioprotective intervention (N = 61).
Outcomes	Heart failure (subclinical heart failure based on LVEF; diagnostic test nm); in the abstract no dichotomous results were provided. Adverse effects (no definition provided) Bone marrow suppression: in the intervention group; grade III N = 15 (24.6%), grade IV N = 3 (4.9%) and in the control group; grade III N = 6 (9.8%), grade IV N = 3 (5.5%). Neutrophil count: in the abstract no dichotomous results were provided.
Notes	The full text is available in Chinese, results presented here are based on the English abstract. As of yet, unclear if this study is eligible for inclusion. Median time since diagnosis nm. Cumulative anthracycline dose per treatment group nm. Age per treatment group nm.